What is the role of the Ki-67 proliferative assay in in the workup of B-cell mantle cell lymphomas (MCL)?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

In addition, both the NCCN and ESMO recommend assaying Ki-67 proliferative antigen to evaluate cell proliferation. Low Ki-67 (< 30%) is associated with a more favorable prognosis; however, it is not used to guide treatment decisions. [16, 31]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!